Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis‐associated inflammatory bowel disease (PSC‐IBD): A matched analysis from the Paediatric PSC Consortium.
Saved in:
| Title: | Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis‐associated inflammatory bowel disease (PSC‐IBD): A matched analysis from the Paediatric PSC Consortium. |
|---|---|
| Authors: | Ricciuto, Amanda1 (AUTHOR) amanda.ricciuto@sickkids.ca, Liu, Kuan2 (AUTHOR), El‐Matary, Wael3 (AUTHOR), Amin, Mansi4 (AUTHOR), Amir, Achiya Z.5 (AUTHOR), Aumar, Madeleine6 (AUTHOR), Auth, Marcus7 (AUTHOR), Di Guglielmo, Matthew D.8 (AUTHOR), Druve Tavares Fagundes, Eleonora9 (AUTHOR), Rodrigues Ferreira, Alexandre10 (AUTHOR), Furuya, Katryn N.11 (AUTHOR), Gupta, Nitika12 (AUTHOR), Guthery, Stephen13 (AUTHOR), Horslen, Simon P.14 (AUTHOR), Jensen, Kyle13 (AUTHOR), Kamath, Binita M.1 (AUTHOR), Kerkar, Nanda15 (AUTHOR), Koot, B. G. P.16 (AUTHOR), Laborda, Trevor J.13 (AUTHOR), Lee, Christine K.17 (AUTHOR) |
| Source: | Alimentary Pharmacology & Therapeutics. May2024, Vol. 59 Issue 10, p1236-1247. 12p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 02692813 |
|---|---|
| DOI: | 10.1111/apt.17936 |
